The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer DOI Open Access
Małgorzata Szostakowska-Rodzoś, Ewa A. Grzybowska, Izabella Myśliwy

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2038 - 2038

Опубликована: Фев. 26, 2025

Monitoring of metastatic breast cancer (mBC) is an important issue in the clinical management patients. Liquid biopsy has become a non-invasive method for detecting and monitoring body fluids. The presence circulating tumor cells (CTCs) DNA (ctDNA) peripheral blood indicates poor prognosis may contribute to early detection progression, but assessment these levels still not routine management. main objective this study was estimate frequency value ESR1 PIK3CA mutations identified free (cfDNA.) second goal evaluate whether simultaneous evaluation CTCs mutation status cfDNA increases prognostic liquid biopsy. results analysis CTC number collected from 179 patients with show that are more frequent advanced luminal regardless type treatment. appear primarily during as no were found primary samples. conclusion combined improve

Язык: Английский

The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer DOI Open Access
Małgorzata Szostakowska-Rodzoś, Ewa A. Grzybowska, Izabella Myśliwy

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2038 - 2038

Опубликована: Фев. 26, 2025

Monitoring of metastatic breast cancer (mBC) is an important issue in the clinical management patients. Liquid biopsy has become a non-invasive method for detecting and monitoring body fluids. The presence circulating tumor cells (CTCs) DNA (ctDNA) peripheral blood indicates poor prognosis may contribute to early detection progression, but assessment these levels still not routine management. main objective this study was estimate frequency value ESR1 PIK3CA mutations identified free (cfDNA.) second goal evaluate whether simultaneous evaluation CTCs mutation status cfDNA increases prognostic liquid biopsy. results analysis CTC number collected from 179 patients with show that are more frequent advanced luminal regardless type treatment. appear primarily during as no were found primary samples. conclusion combined improve

Язык: Английский

Процитировано

0